1 INTRODUCTION
==============

Autoimmune polyglandular syndrome type 1 (APS-1) also known as autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED; OMIM 240300) is rare but devastating primary immunodeficiency disease. The range of clinical features is broad and very variable. The classic triad includes chronic mucocutaneous candidiasis (CMC), hypoparathyroidism (HP) and Addison's disease (AD). Patients may develop several other autiommune endocrine disorders (gonadal failure, type 1 diabetes, autoimmune thyroid disease) and nonendocrine disorders (ectodermal dystrophy, alopecia, vitiligo, chronic hepatitis...) ([@b1-sjph-54-02-112]). The disease usually begins in infancy with CMC, additional symptoms gradually appear later in life. Clinical diagnosis requires the presence of two of three major criteria (CMC, HP, AD). If a sibling has the syndrome, only one of the above manifestations is required. The prevalence is higher in genetically isolated populations; in Slovenia it was estimated to be 1:43,000 ([@b2-sjph-54-02-112]). APS-1 is caused by autosomal recessively inherited mutations in autoimmune regulator (*AIRE*) gene ([@b3-sjph-54-02-112]). *AIRE* gene is encoding transcriptional regulator principally expressed in medullary thymic epithelial cells (mTEC). *AIRE* plays an important role in maintaining self-tolerance and is involved in negative selection of autoreactive T-cells ([@b4-sjph-54-02-112]). The absence of *AIRE* results in impaired clonal deletion of self reactive thymocytes, which escape into the periphery and attack variety of organs resulting in different autoimmune diseases and presence of different organ specific autoantibodies ([@b5-sjph-54-02-112]). Additionally some non-organ specific auto-antibodies are characteristic to APS-1. Antibodies against type I interferons, especially α and ω subtypes are reported to be highly specific for APS-1 ([@b6-sjph-54-02-112]). More recently, CMC in APS-1 patients have been associated with autoantibodies against Th17-related cytokines, primarily against IL-22 and IL-17F ([@b7-sjph-54-02-112]) showing that also CMC in APS-1 has an autoimmune basis.

2 METHODS
=========

Fifteen APS-1 patients from thirteen unrelated Slovenian families were identified and included into the study. Mutational and partial clinical characteristics of patients 1 to 12 were previously reported ([@b2-sjph-54-02-112], [@b8-sjph-54-02-112]). Those patients were reinvestigated for the purposes of this study. The study protocol followed the Declaration of Helsinki and was approved by the national Ethical Committee (nr. 22/09/09, 28/2/13). Written informed consent was obtained by all participants or parents of minors prior to the study.

The patients' data were collected from existing medical records. The diagnosis of HP, AD, primary hypothyroidism, primary gonadal failure, pituitary failure were based on typical biochemical and endocrinological findings as described by others ([@b9-sjph-54-02-112]). We diagnosed oral candidiasis by visible mucosal changes in combination with positive Candida albicans culture and nail candidiasis by typical clinical findings or with the help of experienced dermatologist. Malabsorption was diagnosed from a history of recurrent episodes of diarrhea, growth retardation and/or measurement of fecal fat and pancreatic enzymes in stool. The duodenal and short bowel biopsy with chromogranin staining for detection of enterochromaffin cells was performed. Chronic elevation of liver enzymes without evidence of viral or drug-induced hepatitis was considered as suspected of autoimmune hepatitis. Consequently, liver biopsy and detection of autoantibodies against cytochrome P4501A2 (CYP1A2) were issued. Enamel hypoplasia was defined as defects in enamel not due to caries and the patients were evaluated by clinical examination and an orthopantomogram by an experienced dentist.

Genomic DNA was isolated from venous blood samples and *AIRE* gene exons were individually PCR amplified ([@b2-sjph-54-02-112]). Sequencing was performed using BigDye Terminator v.3.1 Cycle Sequencing Kit and 3500 Genetic Analyzer capillary electrophoresis system (Life Technologies, Foster City, USA). Identified variants were confirmed by the sequencing of at least two independent PCR products. Anti-IFN-α2, anti-IFN-α8, anti-IL-22, anti-IL-17A and anti-IL-17F autoantibodies were measured in 12 out of 15 patients by luminescence immunoprecipitation system (LIPS) as previously described ([@b10-sjph-54-02-112]).

3 RESULTS
=========

3.1 Clinical Characteristics
----------------------------

In surveys performed in 2005 and again in 2012 we were able to identify fifteen patients from thirteen families. Their clinical manifestations and the age of onset are shown in [Table 1](#t1-sjph-54-02-112){ref-type="table"}. All recruited patients but one had either two of the three major clinical manifestations or one in combination with blood relative with established APS-1. Mutational analysis confirmed the diagnosis in the patient with CMC as the only clinical manifestation.

Among 11 boys and 4 girls, the onset of the disease ranged from 1,8 years to 10,9 years (mean 6,1 yr). HP was the first clinical manifestation in seven patients, AD in five, autoimmune hepatitis, autoimmune thyroiditis and CMC each in one. In three patients with HP or autoimmune thyroiditis as first manifestation, review of the available clinical data revealed that MC was present much earlier.

The patients had one to eight clinical manifestations. CMC was present in all patients, HP in 12 (80 %), AD in 8 (53 %), autoimmune thyroiditis and hypogonadism each in 6 (40 %). Other clinical manifestations appeared less often ([Figure 1](#f1-sjph-54-02-112){ref-type="fig"}). AD was diagnosed in all patients in the first decade of life. Mineralocorticoid deficiency preceded hypocorticism in 3/8 patients (5/D, 6/E, 10/H). Hypogonadism was diagnosed in 2 girls and 4 boys during or after pubertal development. One male patient (4/C) had secondary hypogonadism in the course of autoimmune hypophysitis, all other patients had primary hypogonadism. Keratoconjuctivitis was diagnosed in three patients. In one of (4/C) them the changes improved only after long term systemic cyclosporine treatment.

Seven patients (46 %) had growth retardation from different causes shown in [Table 2](#t2-sjph-54-02-112){ref-type="table"}. Growth hormone deficiency was confirmed only in patient 4/C with secondary hypogonadism and several other clinical manifestations. In the female patient 11/I exaggerated response during growth hormone stimulation test and normal growth factors were observed.

Autoimmune thyroiditis with myxoedema and severe growth retardation was the first clinical manifestation of APS-1 in patient 12/J at the age of 5,5 years. After starting treatment with L-thyroxine, his growth velocity increased and he reached normal growth curves. Growth failure reappeared at the age of 14 years when steatorrhea and pancreatic insufficiency was diagnosed. Chronic corticosteroid treatment of autoimmune hepatitis caused growth delay in patient 10/H.

Depression was observed in three (4/C, 7/E, 11/I) patients who needed psychiatric support. During the study period, two young adult patients (8/F, 9/G) died, both with severe psychological dysfunction. One died due to addisonian crisis, after having neglected therapy for a long time. The other patient most probably died because of insulin overdose.

3.2 Mutational and Immunological Characteristics
------------------------------------------------

Six different *AIRE* gene mutations were detected among 15 APS-1 patients ([Table 1](#t1-sjph-54-02-112){ref-type="table"}), three of which were novel at the time ([@b2-sjph-54-02-112]). The most prevalent mutation in Slovenian APS-1 population was p.R257\* (c.769C\>T) present in 63.3 % of pathological alleles, followed by p.R15fs (c.21-43dup23) mutation in 16.7 %. Anti-IFN-α2, anti-IFN-α8 and anti-IL-22 autoantibodies in high titres were detected in all analysed patients ([Table 3](#t3-sjph-54-02-112){ref-type="table"}). Anti-IL-17A were detected in 41,7 % and anti-IL-17F in 91,7 % of APS-1 patients.

4 DISCUSSION
============

While the majority of reports are focusing on adult APS-1 patients, so far there is only one report describing clinical and genetic characteristics of paediatric North Irish APS-1 patients ([@b11-sjph-54-02-112]). Here, we report extensive clinical, genetic and immunological overview of Slovenian paediatric APS-1 cohort.

Whereas all but one patient in our study group met standard diagnostic APS-1 criteria, there were striking clinical variations, even between siblings with identical *AIRE* mutations. Clinical manifestations showed similar prevalence and follow-up as in those reported in other studies ([@b11-sjph-54-02-112]--[@b13-sjph-54-02-112]). Especially as in Finnish patients, with whom the majority of Slovenian patients share the common p.R257\* (c.769C\>T) mutation ([@b1-sjph-54-02-112]). CMC was detected in all Slovenian and Finnish patients, while it was present in less than 20 % of Iranian Jews patients, probably due to *AIRE* mutation present only in this community ([@b14-sjph-54-02-112]). On the contrary, type I diabetes was observed in only one Slovenian patient, but it is more frequent among Finnish patients ([@b1-sjph-54-02-112]).

The APS-1 patients were usually first admitted to our clinic because of clinical symptoms of hypoparathyroidism, Addison's disease, or symptoms of other endocrine or organ dysfunction, while it is possible that Candida albicans infection was present much earlier. At clinical examination, Candida infection was detected in 6 out of 15 (40 %) patients by the age of 5, and in all of them by the age of 25 years old. This is comparable to the Finnish data, where 50 % had candidiasis by the age of 5 and 97 % by the age of 30 ([@b15-sjph-54-02-112]).

Only individual cases of growth failure in APS-1 have been published to date ([@b11-sjph-54-02-112], [@b16-sjph-54-02-112], [@b17-sjph-54-02-112]). Nevertheless, growth failure as clinical presentation of various endocrine and nonendocrine dysfunctions, was observed in 46 % of Slovenian patients. The patient 4/C with growth hormone deficiency had hypersensitivity to growth hormone, which has not been reported in APS-1 so far. During growth hormone treatment, systemic allergic reaction occurred and the treatment was discontinued. In the patient 11/I with growth hormone resistance, the treatment with high doses of growth hormone did not improve her growth velocity, despite a significant increase in the growth factors level. We speculated that antibodies against growth factors or growth factor receptors may be responsible, but further investigations are needed.

APS-1 should be considered in the differential diagnosis of gastrointestinal symptoms, such as malabsorption, constipation, watery diarrhea or steatorrhea, as they are reported in almost 24 % of the APS-1 patients ([@b17-sjph-54-02-112]). Several studies demonstrated that gastrointestinal dysfunction (GD) in APS-1 patients is associated with severe or complete loss of enteroendocrine cells ([@b18-sjph-54-02-112]--[@b20-sjph-54-02-112]). Patients develop autoantibodies against tryptophan hydroxylase, the rate-limiting enzyme in the synthesis of serotonin, having a critical role in enteric function ([@b19-sjph-54-02-112]). The identification of mucosal antibodies and repeated clinical remission achieved with immunosuppressive treatment in a patient with recurrent episodes of diarrhea with steatorrhea clearly support the idea that GD is due to *AIRE* deficiency ([@b21-sjph-54-02-112]). We observed GD in four patients (3/B, 6/E, 7/E, 12/J). All had intestinal candidiasis treated with systemic antifungal therapy, one of them additional massive duodenal colonisation with Giardia lamblia (7/E). Three patients (6/E, 7/E, 12/J) had recurring diarrhea and steatorrhea with exocrine pancreatic insufficiency, in two absence of enteroendocrine cells in intestinal biopsy was found.

Chronic endocrine disorders are known to impair patients' quality of life. APS-1 patients not only cumulate multiple endocrine disorders, requiring daily oral and lifelong hormonal replacement therapy, but the disease affects the quality of life in numerous ways: by life-threatening situations, disfiguring ectodermal manifestations, vision impairment, infertility and fear of developing additional components during life. Impairment of general health, emotional well-being and vitality were the most diminishing aspects of quality of life, with depressive symptoms affecting 29 % of the adult APS-1 Finnish patients ([@b22-sjph-54-02-112]). Among Slovenian paediatric APS-1 patients, three developed depression and two young adults died. This is indicating the extent of the disease burden even in younger patients.

Over 95 different *AIRE* mutations have been identified, but two of them are found in the great majority of the patients. The p.Cys322fs (c.967_979del13) mutation is characteristic of North American, British and Norwegian patients ([@b23-sjph-54-02-112]), p.R257\* (c.769C\>T) is present in more than 85 % of the Finnish patients and common among Central and Eastern European patients ([@b12-sjph-54-02-112],[@b24-sjph-54-02-112]). Mutational spectrum of Slovenian APS-1 patients was consistent with other populations in the region, since p.R257\* mutation was present in 63,3 % of pathological *AIRE* alleles. The second most prevalent mutation was p.R15fs (c.21-43dup23bp). This mutation was reported only in one Austrian and one Hungarian patient ([@b24-sjph-54-02-112]), and it seems to be restricted to the region. Other mutations are much rarer and present in isolated families.

A great variability in the prevalence of autoimmune hepatitis in different populations is reported, namely: 5 % in Norwegian ([@b25-sjph-54-02-112]), 12 % in Finish ([@b9-sjph-54-02-112]) and 27 % in Sardinian patients ([@b26-sjph-54-02-112]). These populations differ highly in their *AIRE* gene mutational spectrum ([@b23-sjph-54-02-112]--[@b25-sjph-54-02-112]), and it seems that the prevalence of autoimmune hepatitis might be related to it. A great majority of Slovenian and Finnish APS-1 patients carry the same *AIRE* mutation, and the prevalence of autoimmune hepatitis in both cohorts is comparably low. The hallmark of APS-1 is a variety of different autoantibodies that develop in association with the disease, where numerous organ specific, but also non-organ specific, autoantibodes may be present. Among the latter, antibodies against α and ω subtypes of type I interferons are present in all patients with APS-1, and, additionally, only in patients with thymoma with associated myasthenia gravis, but not in other autoimmune disorders ([@b27-sjph-54-02-112]). The autoantibodies are reported to be present before the onset of the disease ([@b6-sjph-54-02-112]). In our group of patients, anti-IFN-α2 and anti-IFN-α8 autoantibodies were present in all analysed patients, even in the patient 13/K, whose only symptom was CMC, and who had an uncommon *AIRE* mutation. This was confirming their diagnostic value in children with incomplete APS-1 clinical presentation.

Chronic mucocutaneous candidiasis is a persistent or recurrent infection of nail beds, skin or mucosa. It is the most prevalent disease manifestation associated with APS-1, present in all Slovenian patients. CMC in APS-1 have been associated with autoantibodies against Th17-related cytokines, revealing the link between CMC and *AIRE* deficiency. Neutralizing autoantibodies against IL-22 are present in 91 %, against IL-17F in 75 % and/or against IL-17A in 41 % of more than 150 analysed patients ([@b7-sjph-54-02-112]). They are highly specific for CMC in APS-1, and are present only in thymoma patients, but not in numerous other autoimmune diseases. Interestingly, all investigated Slovenian patients had anti-IL-22 autoantibodies present. Anti-IL-17F autoantibodies were present in 91 % of the patients, but anti-IL-17A were, as expected, less prevalent.

5 CONCLUSION
============

The phenotypical expression of the APS-1 shows a wide variability even among siblings with the same genotype. In view of this heterogeneity, an early diagnosis of APS-1 can be challenging and often leading to a considerable diagnostic delay. Therefore, clinicians should be aware that the presence of even a minor component of APS-1 in children should prompt a careful investigation for other signs and symptoms of the disease, including genetic and immunological testing, thus allowing an early diagnosis and prevention of severe and life-threatening events. Growth failure in presented population was common, while its aetiology may be diverse and frequently caused by less characteristic manifestations of the syndrome. Psychological burden of the disease was evident and requiring professional psychosocial support in the selected cases.
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###### 

Clinical and mutational characteristics in APS-1 patients (patients with growth retardation are marked with \#; mutations in bold were novel when detected, HP-hypoparathyroidism; AD-Addison's disease; CMC-mucocutaneous candidiasis; Al-alopecia; ED-ectodermal dystrophy; KK-keratoconjunctivitis; Vi-vitiligo; T1D-type 1 diabetes, AH-autoimmune hepatitis; Ht-hypothyroidism; Ma-malabsorption; Hg-hypogonadism).

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient/Family   Gender   Year of birth   Clinical characteristics   *AIRE* mutation                                                                    
  ---------------- -------- --------------- -------------------------- ----------------- ------ ----- ----- ------ ------ ---- ----- ------ ------ ------ ----------------------------------------------------
  **1/A**          M        1979            14                         10                12                                                               p.\[R257\*\];\[R257\*\]\
                                                                                                                                                          c.\[769C\>T\];\[769C\>T\]

  **2/A**          M        1980            6,3                                          17,5   7,0                                                       p.\[R257\*\];\[R257\*\]\
                                                                                                                                                          c.\[769C\>T\];\[769C\>T\]

  **3/B\#**        F        1990            7,8                        7,9               7,9                                                13,5   20,9   p.\[R257\*\];\[R257\*\]\
                                                                                                                                                          c.\[769C\>T\];\[769C\>T\]

  **4/C\#**        M        1990            6,5                        6,4               6,5          6,5   10,3                     11,1          14,8   p.\[R257\*\];\[R257\*\]\
                                                                                                                                                          c.\[769C\>T\];\[769C\>T\]

  **5/D**          M        1986            11,1                       10,9              11,1               13,1                     25                   p.\[R257\*\];\[R257\*\]\
                                                                                                                                                          c.\[769C\>T\];\[769C\>T\]

  **6/E\#**        M        1997            3,7                        14,9              3,7    3,7   3,7                            9,7    6,3           p.\[R257\*\];\[T16M\]\
                                                                                                                                                          c.\[769C\>T\];\[47C\>T\]

  **7/E\#**        F        1992            5,5                                          11,4         5,5                                   15,9          p.\[R257\*\];\[T16M\]\
                                                                                                                                                          c.\[769C\>T\];\[47C\>T\]

  **8/F**          M        1977                                       7,8               23,3         7,8                            26,3          21,3   p.\[R257\*\];\[R15fs\]\
                                                                                                                                                          c.\[769C\>T\];\[21-43dup23\]

  **9/G**          M        1976            9,4                                          24,5   9                  11,6   21         24,5                 p.\[R257\*\];\[**G180fs**\]\
                                                                                                                                                          c.\[769C\>T\];\[**540delG**\]

  **10/H\#**       M        1992                                       8,5               3,6    3,6                            3,6                 17,8   p.\[R257\*\];\[R257\*\]\
                                                                                                                                                          c.\[769C\>T\];\[769C\>T\]

  **11/I\#**       F        1998            3,8                        4,0               4,6                12,5                                   11,7   p.\[R257\*\];\[?\]\
                                                                                                                                                          c.\[769C\>T\];\[**653-7\_-5delCTC**\]

  **12/J\#**       M        1990            12,9                                         0,3          5,5                            5,5    14,5   20,7   **p.\[Q358fs\];\[Q358fs\]**\
                                                                                                                                                          **c.\[1064-1068dupCCCGG\]; \[1064-1068dupCCCGG\]**

  **13/K**         M        1998                                                         1,8                                                              p.\[R15fs\];\[R15fs\]\
                                                                                                                                                          c.\[21-43dup23\];\[21-43dup23\]

  **14/L**         M        2004            7,9                                          5,8                                                              p.\[R15fs\];\[R15fs\]\
                                                                                                                                                          c.\[21-43dup23\];\[21-43dup23\]

  **15/M**         F        2009            3,3                                          2,5                                                              p.\[R257\*\];\[R257\*\]\
                                                                                                                                                          c.\[769C\>T\];\[769C\>T\]
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Etiology of growth retardation in APS 1 patients.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Growth hormone deficiency
  Growth hormone resistance
  Chronic corticosteroid therapy
  Hypothyroidism (autoimmune thyroiditis)
  Malabsorption: Massive duodenal colonisation with Giardia lambliaMassive gastrointestinal colonisation with Candida albicansExocrine pancreatic insufficiencyEnteroendocrine cell loss
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Immunological characteristics of the APS-1 patients (the values represent times over the mean of healthy control values; negative values are in italic).

         Clinical characteristics   anti-IFN-α2   anti-IFN-α8   anti-IL-22   anti-IL-17A   anti-IL-17F
  ------ -------------------------- ------------- ------------- ------------ ------------- -------------
  1/A    3                          133,2         69,2          382,4        *0,7*         13,7
  3/B    5                          pos           pos           pos          pos           pos
  4/C    7                          139,4         112,8         170,5        *1,6*         14,0
  5/D    5                          175,5         145,6         769,7        144,9         62,7
  6/E    7                          278,3         68,0          512,1        *0,7*         25,1
  7/E    4                          149,0         126,1         210,5        *0,7*         *0,8*
  10/H   5                          92,3          149,0         362,5        15,1          110,9
  11/I   5                          101,1         132,0         605,8        *2,2*         201,7
  12/J   6                          242,4         190,8         996,6        *1,5*         86,8
  13/K   1                          280,9         66,3          353,8        114,6         7,7
  14/L   2                          103,6         81,1          533,4        76,1          131,8
  15/M   3                          73,6          127,2         411,0        *3,8*         159,9
                                                                                           
                                    100%          100%          100%         41,7%         91,7%
